Graviton Bioscience

Executive Summary

Graviton Bioscience is a private biotechnology company pioneering selective ROCK2 inhibitors for fibrotic, autoimmune, and central nervous system (CNS) diseases. The company's core strategy is to restore homeostasis by modulating multiple concerted molecular pathways, differentiating its approach from less selective ROCK inhibitors. Founded in 2018 and headquartered in New York, Graviton is currently in Phase 2 development for its lead candidate, targeting fibrotic indications such as idiopathic pulmonary fibrosis (IPF) and potentially systemic sclerosis. The selective inhibition of ROCK2 is thought to reduce fibrosis and inflammation while avoiding immunosuppressive side effects associated with ROCK1 inhibition. With a small molecule pipeline, Graviton aims to address significant unmet medical needs in chronic fibrotic and autoimmune conditions, where current therapies are limited. The company has not yet disclosed total funding or valuation, but its progression to Phase 2 indicates prior successful preclinical and early clinical work. Key upcoming catalysts include Phase 2 data readouts, which could validate the therapeutic hypothesis and support advancement to pivotal trials. Additionally, Graviton may seek strategic partnerships for CNS indications or secure additional financing to expand its pipeline. Given the promising but early-stage nature of its programs, the conviction score for Graviton's long-term success is moderate, reflecting both the potential of ROCK2 inhibition and the inherent risks of clinical development.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for lead ROCK2 inhibitor in fibrotic disease60% success
• H2 2026Partnership or licensing deal for CNS indication40% success
• 2026Series B or C financing round70% success